Nkarta Q2 net loss $33.3M ($0.68/share); cash $302.2M; NKX101 shows 67% CR/CRi with Flu/Ara-C

Nkarta, Inc.

2023-Q2 EPS reported -$1.31

Cash and investments $302.2M as of June 30, 2023; cash runway into 2025.
R&D expense $25.1M; G&A $11.7M; non-cash impairment charge $4.1M on right-of-use assets.
NKX101: 4/6 CR/CRi (67%) in AML patients after Flu/Ara-C lymphodepletion; no dose-limiting toxicities.
NKX019 updated data from Phase 1 NHL trial presented at EHA and ICML; expansion cohorts enrolling.
Alyssa Levin appointed CFO and Chief Business Officer effective July 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nkarta, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $33.3 million, or $0.68 per basic and diluted share, EPS $0.68 per basic and diluted share.

Period: second quarter ended June 30, 2023
Net income: Net loss was $33.3 million, or $0.68 per basic and diluted share
EPS: $0.68 per basic and diluted share
Result: reported results

Exact text from the filing

Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights

View on SEC.gov

Browse all earnings releases →

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.